FDG-PET for Evaluating the Antitumor Effect of Intraarterial 3-Bromopyruvate Administration in a Rabbit VX2 Liver Tumor Model.
- Author:
Hee Sun PARK
1
;
Jin Wook CHUNG
;
Hwan Jun JAE
;
Young Il KIM
;
Kyu Ri SON
;
Min Jong LEE
;
Jae Hyung PARK
;
Won Jun KANG
;
Jung Hwan YOON
;
Hesson CHUNG
;
Kichang LEE
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: Liver neoplasm, therapeutic radiology; Liver, interventional procedure; Liver, PET
- MeSH: Animals; Disease Models, Animal; Enzyme Inhibitors/*pharmacology; Feasibility Studies; Fluorodeoxyglucose F18; Infusions, Intra-Arterial; Injections, Intra-Arterial; Liver Neoplasms, Experimental/*drug therapy/pathology/*radionuclide imaging; Necrosis; *Positron-Emission Tomography; Pyruvate Dehydrogenase Complex/antagonists & inhibitors; Pyruvates/*pharmacology; Rabbits; Radiopharmaceuticals
- From:Korean Journal of Radiology 2007;8(3):216-224
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: We wanted to investigate the feasibility of using FDG-PET for evaluating the antitumor effect of intraarterial administration of a hexokinase II inhibitor, 3-bromopyruvate (3-BrPA), in a rabbit VX2 liver tumor model. MATERIALS AND METHODS: VX2 carcinoma was grown in the livers of ten rabbits. Two weeks later, liver CT was performed to confirm appropriate tumor growth for the experiment. After tumor volume-matched grouping of the rabbits, transcatheter intraarterial administration of 3-BrPA was performed (1 mM and 5 mM in five animals each, respectively). FDG-PET scan was performed the day before, immediately after and a week after 3-BrPA administration. FDG uptake was semiquantified by measuring the standardized uptake value (SUV). A week after treatment, the experimental animals were sacrificed and the necrosis rates of the tumors were calculated based on the histopathology. RESULTS: The SUV of the VX2 tumors before treatment (3.87+/-1.51[mean+/-SD]) was significantly higher than that of nontumorous liver parenchyma (1.72+/-0.34) (p < 0.0001, Mann-Whitney U test). The SUV was significantly decreased immediately after 3-BrPA administration (2.05+/-1.21) (p = 0.002, Wilcoxon signed rank test). On the one-week follow up PET scan, the FDG uptake remained significantly lower (SUV 1.41+/-0.73) than that before treatment (p = 0.002), although three out of ten animals showed a slightly increasing tendency for the FDG uptake. The tumor necrosis rate ranged from 50.00% to 99.90% (85.48%+/-15.87). There was no significant correlation between the SUV or the SUV decrease rate and the tumor necrosis rate in that range. CONCLUSION: Even though FDG-PET cannot exactly reflect the tumor necrosis rate, FDG-PET is a useful modality for the early assessment of the antitumor effect of intraarterial administration of 3-BrPA in VX2 liver tumor.
